Top

Published in:

01-12-2013 | Review Article

Cutaneous Drug Reactions in Children: An Update

Authors: Kara Heelan, Neil H. Shear

Published in: Pediatric Drugs | Issue 6/2013

Abstract

Cutaneous drug reactions account for a large proportion of adverse drug reactions. Cutaneous drug reactions can be very challenging to diagnose. They can mimic many other skin diseases; this is especially evident during childhood, when viral exanthems are commonplace. Also, if a patient is taking numerous medications, establishing causality to a specific drug can be multifaceted and difficult. The purpose of this review is to highlight an approach to the diagnosis of a suspected cutaneous drug reaction in a child. We have classified different types of drug eruptions by morphology: exanthematous, urticarial, pustular, and bullous. Within each of these groups we have divided them into simple, benign, or non-febrile and complex or febrile reactions. We also include a miscellaneous group to ensure a methodical review.

Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics. 2007;120(4):e1082–96.PubMedCrossRef

Star K, Noren GN, Nordin K, Edwards IR. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf. 2011;34(5):415–28.PubMedCrossRef

Castro-Pastrana LI, Ghannadan R, Rieder MJ, Dahlke E, Hayden M, Carleton B. Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). J Popul Ther Clin Pharmacol. 2011;18:e106–20.PubMed

Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52(1):77–83.PubMedCrossRef

Gallagher RM, Mason JR, Bird KA, Kirkham JJ, Peak M, Williamson PR, et al. Adverse drug reactions causing admission to a paediatric hospital. PLoS One. 2012;7(12):e50127.PubMedCrossRef

Smyth RM, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, et al. Adverse drug reactions in children—a systematic review. PLoS One. 2012;7(3):e24061.PubMedCrossRef

Menniti-Ippolito G, Raschetti R, Da Cas R, Giaquinto C, Cantarutti L. Active monitoring of adverse drug reactions in children. Italian Paediatric Pharmacosurveillance Multicenter Group. Lancet. 2000;355(9215):1613–4.PubMedCrossRef

Ibia EO, Schwartz RH, Wiedermann BL. Antibiotic rashes in children: a survey in a private practice setting. Arch Dermatol. 2000;136(7):849–54.PubMedCrossRef

Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E, et al. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther. 2011;89(6):896–901.PubMedCrossRef

10.

Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003;2(3):278–99.PubMed

11.

Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256(24):3358–63.PubMedCrossRef

12.

Naranjo CA, Shear NH, Lanctot KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol. 1992;32(10):897–904.PubMedCrossRef

13.

Stern RS. Clinical practice: exanthematous drug eruptions. N Engl J Med. 2012;366(26):2492–501.PubMedCrossRef

14.

Yawalkar N. Maculopapular drug eruptions. Basel: Karger; 2007. p. 242–51.

15.

Crowson AN, Magro CM. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin. 1999; 17(3):537–60, viii.

16.

Carroll MC, Yueng-Yue KA, Esterly NB, Drolet BA. Drug-induced hypersensitivity syndrome in pediatric patients. Pediatrics. 2001;108(2):485–92.PubMedCrossRef

17.

Kress DW. Pediatric dermatology emergencies. Curr Opin Pediatr. 2011;23(4):403–6.PubMedCrossRef

18.

Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272–85.PubMedCrossRef

19.

Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97.PubMedCrossRef

20.

Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010;146(12):1373–9.PubMedCrossRef

21.

Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009;145(1):67–72.PubMedCrossRef

22.

Hunter EB, Johnston PE, Tanner G, Pinson CW, Awad JA. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol. 1999;94(8):2299–301.PubMedCrossRef

23.

Gupta A, Eggo MC, Uetrecht JP, Cribb AE, Daneman D, Rieder MJ, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther. 1992;51(1):56–67.PubMedCrossRef

24.

Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: In vitro assessment of risk. J Clin Invest. 1988;82(6):1826–32.PubMedCrossRef

25.

Newell BD, Moinfar M, Mancini AJ, Nopper AJ. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). Pediatr Dermatol. 2009;26(5):536–46.PubMedCrossRef

26.

Tamayo-Sanchez L, Ruiz-Maldonado R, Laterza A. Acute annular urticaria in infants and children. Pediatr Dermatol. 1997;14(3):231–4.PubMedCrossRef

27.

Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765–70.PubMed

28.

Twarog FJ. Urticaria in childhood: pathogenesis and management. Pediatr Clin N Am. 1983;30(5):887–98.

29.

Bilbao A, Garcia JM, Pocheville I, Gutierrez C, Corral JM, Samper A, et al. Round table: urticaria in relation to infections [article in Spanish]. Allergol Immunopathol (Madr). 1999;27(2):73–85.PubMed

30.

Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother. 1997;31(5):633–5.PubMed

31.

Poon M, Reid C. Do steroids help children with acute urticaria? Arch Dis Child. 2004;89(1):85–6.PubMed

32.

Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS, Frank MM. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med. 1984;311(22):1407–13.PubMedCrossRef

33.

Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr. 1994;125(5 Pt 1):805–11.PubMedCrossRef

34.

Ashraf-Benson S, Wall GC, Veach LA. Serum sickness-like reaction associated with efalizumab. Ann Pharmacother. 2009;43(2):383–6.PubMed

35.

Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol. 2006;96(4):624–7.PubMedCrossRef

36.

Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol. 2007;13(2):94–5.PubMedCrossRef

37.

Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med. 2006;30(1):41–4.PubMedCrossRef

38.

Grosen A, Julsgaard M, Christensen LA. Serum sickness-like reaction due to Infliximab reintroduction during pregnancy. J Crohns Colitis. 2013;7(5):e191.PubMedCrossRef

39.

Sarma N, Malakar S, Lahiri K, Banerjee U. Serum sickness like reaction with minocycline. Indian J Dermatol Venereol Leprol. 2004;70(1):43–4.PubMed

40.

Katta R, Anusuri V. Serum sickness-like reaction to cefuroxime: a case report and review of the literature. J Drugs Dermatol. 2007;6(7):747–8.PubMed

41.

Parra FM, Perez Elias MJ, Cuevas M, Ferreira A. Serum sickness-like illness associated with rifampicin. Ann Allergy. 1994;73(2):123–5.PubMed

42.

Slama TG. Serum sickness-like illness associated with ciprofloxacin. Antimicrob Agents Chemother. 1990;34(5):904–5.PubMedCrossRef

43.

Ralph ED, John M, Rieder MJ, Bombassaro AM. Serum sickness-like reaction possibly associated with meropenem use. Clin Infect Dis. 2003;36(11):E149–51.PubMedCrossRef

44.

Brucculeri M, Charlton M, Serur D. Serum sickness-like reaction associated with cefazolin. BMC Clin Pharmacol. 2006;6:3.PubMedCrossRef

45.

Colton RL, Amir J, Mimouni M, Zeharia A. Serum sickness-like reaction associated with griseofulvin. Ann Pharmacother. 2004;38(4):609–11.PubMedCrossRef

46.

Park H, Knowles S, Shear NH. Serum sickness-like reaction to itraconazole. Ann Pharmacother. 1998;32(11):1249.PubMedCrossRef

47.

Waibel KH, Katial RK. Serum sickness-like reaction and bupropion. J Am Acad Child Adolesc Psychiatry. 2004;43(5):509.PubMedCrossRef

48.

Phillips EJ, Knowles SR, Shear NH. Serum sickness-like reaction associated with clopidogrel. Br J Clin Pharmacol. 2003;56(5):583.PubMedCrossRef

49.

Shapiro LE, Knowles SR, Shear NH. Fluoxetine-induced serum sickness-like reaction. Ann Pharmacother. 1997;31(7–8):927.PubMed

50.

Aujero MP, Brooks S, Li N, Venna S. Severe serum sickness-like type III reaction to insulin detemir. J Am Acad Dermatol. 2011;64(6):e127–8.PubMedCrossRef

51.

Azik FM, Kanmaz G, Ileri T. Serum sickness-like syndrome after immunoglobulin M-enriched polyclonal immunoglobulin. Drug Metabol Drug Interact. 2010;25(1–4):49–50.PubMed

52.

Harris A, Eswaran S, Bosworth B, Gambarin-Gelwan M, Scherl EJ. Mesalamine-induced pneumonitis and serum sickness-like reaction. Gastroenterol Hepatol (N Y). 2007;3(11):875–7.

53.

Lee HS, Yule S, McKenzie A, Cross S, Reid T, Davidson R, et al. Hypersensitivity reactions to streptokinase in patients with high pre-treatment antistreptokinase antibody and neutralisation titres. Eur Heart J. 1993;14(12):1640–3.PubMedCrossRef

54.

Joubert GI, Hadad K, Matsui D, Gloor J, Rieder MJ. Selection of treatment of cefaclor-associated urticarial, serum sickness-like reactions and erythema multiforme by emergency pediatricians: lack of a uniform standard of care. Can J Clin Pharmacol. 1999;6(4):197–201.PubMed

55.

Vial T, Pont J, Pham E, Rabilloud M, Descotes J. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother. 1992 Jul-Aug;26(7-8):910-4.

56.

Grammer LC. Cefaclor serum sickness. JAMA. 1996;275(15):1152–3.PubMed

57.

Hurwitz RM. Steroid acne. J Am Acad Dermatol. 1989;21(6):1179–81.PubMedCrossRef

58.

Traupe H, von Muhlendahl KE, Bramswig J, Happle R. Acne of the fulminans type following testosterone therapy in three excessively tall boys. Arch Dermatol. 1988;124(3):414–7.PubMedCrossRef

59.

Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)—a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113–9.PubMedCrossRef

60.

Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, et al. Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol. 1991;127(9):1333–8.PubMedCrossRef

61.

Meadows KP, Egan CA, Vanderhooft S. Acute generalized exanthematous pustulosis (AGEP), an uncommon condition in children: case report and review of the literature. Pediatr Dermatol. 2000;17(5):399–402.PubMedCrossRef

62.

Ersoy S, Paller AS, Mancini AJ. Acute generalized exanthematous pustulosis in children. Arch Dermatol. 2004;140(9):1172–3.PubMedCrossRef

63.

Fernando SL. Acute generalised exanthematous pustulosis. Australas J Dermatol. 2012;53(2):87–92.PubMedCrossRef

64.

Schmid S, Kuechler PC, Britschgi M, Steiner UC, Yawalkar N, Limat A, et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol. 2002;161(6):2079–86.PubMedCrossRef

65.

De Silva B, Banney L, Uttley W, Luqmani R, Schofield O. Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis. Pediatr Dermatol. 2000;17(6):480–3.PubMedCrossRef

66.

Lang BA, Finlayson LA. Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. J Pediatr. 1994;124(4):639–42.PubMedCrossRef

67.

Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. 2011;29(4):455–7.PubMedCrossRef

68.

Cetkovska P, Pizinger K. Childhood pemphigus associated with montelukast administration. Clin Exp Dermatol. 2003;28(3):328–9.PubMedCrossRef

69.

Purvis DJ, Bhogal BS, Harper JI. Bullous pemphigoid in an infant using complementary medicine. Clin Exp Dermatol. 2009;34(2):195–8.PubMedCrossRef

70.

Fisler RE, Saeb M, Liang MG, Howard RM, McKee PH. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Am J Dermatopathol. 2003;25(3):183–9.PubMedCrossRef

71.

Erbagci Z. Childhood bullous pemphigoid following hepatitis B immunization. J Dermatol. 2002;29(12):781–5.PubMed

72.

Wojnarowska F, Marsden RA, Bhogal B, Black MM. Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults: a comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol. 1988;19(5 Pt 1):792–805.PubMedCrossRef

73.

Nantel-Battista M, Al Dhaybi R, Hatami A, Marcoux D, Desroches A, Kokta V. Childhood linear IgA bullous disease induced by trimethoprim-sulfamethoxazole. J Dermatol Case Rep. 2010;19:4(3):33–5.

74.

Ho JC, Ng PL, Tan SH, Giam YC. Childhood linear IgA bullous disease triggered by amoxicillin-clavulanic acid. Pediatr Dermatol. 2007;24(5):E40–3.PubMedCrossRef

75.

Koh MJ, Tay YK. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Curr Opin Pediatr. 2009;21(4):505–10.PubMedCrossRef

76.

Finkelstein Y, Soon GS, Acuna P, George M, Pope E, Ito S, et al. Recurrence and outcomes of Stevens–Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128(4):723–8.PubMedCrossRef

77.

Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, et al. Medications as risk factors of Stevens–Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2):e297–304.PubMedCrossRef

78.

Sotozono C, Ueta M, Kinoshita S. Systemic and local management at the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Am J Ophthalmol. 2010;149(2):354 (author reply 5).PubMedCrossRef

79.

Struck MF, Hilbert P, Mockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med. 2010;36(1):22–32.PubMedCrossRef

80.

Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004;428(6982):486.PubMedCrossRef

81.

Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31(1):100–4.PubMedCrossRef

82.

Paquet P, Pierard GE. New insights in toxic epidermal necrolysis (Lyell’s syndrome): clinical considerations, pathobiology and targeted treatments revisited. Drug Saf. 2010;33(3):189–212.PubMedCrossRef

83.

Hanken I, Schimmer M, Sander CA. Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis. J Dtsch Dermatol Ges. 2010;8(5):341–6.PubMedCrossRef

84.

Inamo Y, Okubo T, Wada M, Fuchigami S, Hashimoto K, Fuchigami T, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch Allergy Immunol. 2002;127(1):89–94.PubMedCrossRef

85.

Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7(2):142–60 (quiz 61–2).PubMed

86.

Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of treatment of drug-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011;18:e121–33.PubMed

87.

Khaled A, Kharfi M, Ben Hamida M, El Fekih N, El Aidli S, Zeglaoui F, et al. Cutaneous adverse drug reactions in children: a series of 90 cases. Tunis Med. 2012;90(1):45–50.PubMed

88.

Sharma VK, Dhar S. Clinical pattern of cutaneous drug eruption among children and adolescents in north India. Pediatr Dermatol. 1995;12(2):178–83.PubMedCrossRef

89.

Ott H. Hypersensitivity reactions to drugs. Harper’s textbook of pediatric dermatology, 3rd ed. New York: Wiley; 2011: 183.1–183.14.

90.

Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9(4):316–21.PubMedCrossRef

91.

Ozkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges. 2008;6(3):181–8.PubMedCrossRef

92.

Shih IH, Huang YH, Yang CH, Yang LC, Hong HS. Childhood neutrophilic eccrine hidradenitis: a clinicopathologic and immunohistochemical study of 10 patients. J Am Acad Dermatol. 2005;52(6):963–6.PubMedCrossRef

93.

Shear NH, Knowles SR, Shapiro L, Poldre P. Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. J Am Acad Dermatol. 1996;35(5 Pt 2):819–22.PubMedCrossRef

94.

White-Koning M, Civade E, Geoerger B, Thomas F, Le Deley MC, Hennebelle I, et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin Cancer Res. 2011;17(14):4862–71.PubMedCrossRef

95.

Arkachaisri T, Lehman TJ. Systemic lupus erythematosus and related disorders of childhood. Curr Opin Rheumatol. 1999;11(5):384–92.PubMedCrossRef

96.

Farver DK. Minocycline-induced lupus. Ann Pharmacother. 1997;31(10):1160–3.PubMed

97.

Akin E, Miller LC, Tucker LB. Minocycline-induced lupus in adolescents. Pediatrics. 1998;101(5):926.PubMedCrossRef

98.

Finkel TH, Hunter DJ, Paisley JE, Finkel RS, Larsen GL. Drug-induced lupus in a child after treatment with zafirlukast (Accolate). J Allergy Clin Immunol. 1999;103(3 Pt 1):533–4.PubMedCrossRef

Title: Cutaneous Drug Reactions in Children: An Update
Authors: Kara Heelan
Neil H. Shear
Publication date: 01-12-2013
Publisher: Springer International Publishing
Published in: Pediatric Drugs / Issue 6/2013
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI: https://doi.org/10.1007/s40272-013-0039-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cutaneous Drug Reactions in Children: An Update

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Long-Acting Growth Hormone

Comment on: “Clinical Management of Seizures in Newborns: Diagnosis and Treatment”

Management of Acute Rejection in Paediatric Liver Transplantation

Acknowledgement to Referees

Riluzole as an Adjunctive Therapy to Risperidone for the Treatment of Irritability in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial

Pediatric Health Care Quality Measures: Considerations for Pharmacotherapy